Methotrexate oral solution - Silvergate Pharmaceuticals

Drug Profile

Methotrexate oral solution - Silvergate Pharmaceuticals

Alternative Names: Methotrexate oral liquid - Silvergate Pharmaceuticals; Methotrexate sodium - Silvergate Pharmaceuticals; XATMEP

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Silvergate Pharmaceuticals
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Registered Acute lymphoblastic leukaemia; Juvenile rheumatoid arthritis

Most Recent Events

  • 25 May 2017 Chemical structure information added
  • 25 Apr 2017 Registered for Acute lymphoblastic leukaemia (Combination therapy, In adolescents, In children, In infants, In neonates) in USA (PO)
  • 25 Apr 2017 Registered for Juvenile rheumatoid arthritis (In adolescents, In children, In infants, In neonates, Treatment-experienced) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top